DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Scherpereel A, Mazieres J, Greillier L. et al.
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Lancet Oncol 2019;
20: 239-253
DOI: 10.1016/S1470-2045(18)30765-4.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.